NCT07783802: A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- State
- Under way
- Phase
- Phase 2
- People
- 120 planned
- Started
- 27 Aug 2026
- Primary completion
- May 2027
- Arms
- Clazakizumab Dose 1, Clazakizumab Dose 2, Clazakizumab Dose 3
- Results
- None posted
- 25 Aug 2026: Trial registered
- 27 Aug 2026: Trial started